Biotech Values

[Johnny_C]

Keytruda is still going to be a solid sales performer. This could just be a blip, companies do pull filings for all sorts of reasons. Still, good for BMY.

Selloff in BMY most likely because of people thinking a merge was going to be announced.

Sales up 7 percent and eliquis up nearly 40 percent q3 2016 to q 2017 is huge. Missing a forecast by 2 cents is a silly reason for a selloff. The main takeaway is sales up 7 percent and Opdivo expanding. Who knows what synergies will occur in a merger except top management.